Asia, Neglected Diseases Score Big In Nobel Prize Win
This article was originally published in PharmAsia News
Health campaigners and organizations working in the area of drugs for neglected diseases have hailed the Nobel Prize awarded to three researchers in the field, but the move also highlights shortcomings and research gaps.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.